Published in Front Oncol on January 14, 2014
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med (2014) 0.89
GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol (2014) 0.86
A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules. Arch Biochem Biophys (2016) 0.77
B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol (2017) 0.75
Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials. Sci Rep (2015) 0.75
Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget (2016) 0.75
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer (2017) 0.75
In Vivo Radionuclide Generators for Diagnostics and Therapy. Bioinorg Chem Appl (2016) 0.75
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS One (2017) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med (2009) 2.92
Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med (1994) 2.71
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res (2006) 1.82
Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2005) 1.71
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2004) 1.70
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. J Nucl Med (2009) 1.69
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med (2010) 1.61
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med (2003) 1.56
Processing of clustered DNA damage generates additional double-strand breaks in mammalian cells post-irradiation. Nucleic Acids Res (2004) 1.37
Delayed repair of radiation induced clustered DNA damage: friend or foe? Mutat Res (2010) 1.36
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (2011) 1.30
Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc (2006) 1.27
LETHAL MUTATIONS AND CELL DEATH. Phys Med Biol (1963) 1.22
Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res (1991) 1.21
Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv (2010) 1.20
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A (2003) 1.18
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res (2010) 1.17
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med (1988) 1.16
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1.15
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol (2005) 1.13
Astatine-211: production and availability. Curr Radiopharm (2011) 1.12
An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. J Nucl Med (2002) 1.11
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys (1990) 1.07
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm (2013) 1.05
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging (2010) 1.05
Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med (2010) 1.03
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res (2006) 1.03
Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging (2006) 1.02
Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Cancer Res (1987) 1.00
Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res (2008) 1.00
A formalism for calculation of absorbed dose from radionuclides. Phys Med Biol (1968) 1.00
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res (2003) 0.98
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer (2007) 0.95
IMPAIRMENT OF THE PROLIFERATIVE CAPACITY OF HUMAN CELLS IN CULTURE BY ALPHA-PARTICLES WITH DIFFERING LINEAR-ENERGY TRANSFER. Int J Radiat Biol Relat Stud Phys Chem Med (1964) 0.94
Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol (2013) 0.93
Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol (2003) 0.93
Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res (2001) 0.93
Effects of different ionizing radiations on human cells in tissue culture. III. Experiments with cyclotron-accelerated alpha-particles and deuterons. Radiat Res (1963) 0.93
The in vitro radiobiology of astatine-211 decay. Radiat Res (1986) 0.92
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol (2006) 0.92
A device for the measurement of dose as a function of specific ionization. Radiology (1955) 0.91
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy (2011) 0.89
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood (2011) 0.89
A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol (2003) 0.89
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm (2012) 0.88
Mitochondrial dysfunction resulting from loss of cytochrome c impairs radiation-induced bystander effect. Br J Cancer (2009) 0.87
Effects of different ionizing radiations on human cells in tissue culture. I. Irradiation techniques and dosimetry. Radiat Res (1960) 0.86
Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res (1998) 0.86
Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides (2004) 0.85
Effects of different radiations on human cells in tissue culture. II. Biological experiments. Radiat Res (1960) 0.85
In vivo space radiation-induced non-targeted responses: late effects on molecular signaling in mitochondria. Curr Mol Pharmacol (2011) 0.84
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma. Front Oncol (2013) 0.84
EFFECTS OF DIFFERENT IONIZING RADIATIONS ON HUMAN CELLS IN TISSUE CULTURE. IV. MODIFICATION OF RADIATION DAMAGE. Radiat Res (1964) 0.84
Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol (2013) 0.84
Prospects in folate receptor-targeted radionuclide therapy. Front Oncol (2013) 0.83
The influence of p53 functions on radiation-induced inflammatory bystander-type signaling in murine bone marrow. Radiat Res (2013) 0.83
Radiocolloids in the treatment of ovarian cancer. Obstet Gynecol Surv (1979) 0.82
Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot (2005) 0.82
Alpha-particle microdosimetry. Curr Radiopharm (2011) 0.81
Radiobiology of alpha particles. IV. Cell inactivation by alpha particles of energies 0.4-3.5 MeV. Radiat Res (1993) 0.81
Membrane-dependent bystander effect contributes to amplification of the response to alpha-particle irradiation in targeted and nontargeted cells. Int J Radiat Oncol Biol Phys (2009) 0.80
Protein targeting constructs in alpha therapy. Curr Radiopharm (2011) 0.79
Patient-specific alpha-particle dosimetry. Curr Radiopharm (2011) 0.79
Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol (2012) 0.78
Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.78
Quantitative comparison of radiolabeled antibody therapy and external beam radiotherapy in the treatment of human glioma xenografts. Int J Radiat Oncol Biol Phys (1992) 0.77
Advances in anticancer radiopharmaceuticals. Clin Oncol (R Coll Radiol) (2013) 0.77
Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys (2004) 0.77
Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa. Anal Chem (2008) 0.76
Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr Med Chem (2014) 0.76